Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Priti Kothari

Child & Adolescent Psychiatry Boca Raton, FL Medical Doctor

NPI 1306936745 CMS profile 195054

9960 Central Park Blvd N, Ste. 235, Boca Raton, FL 33428

Open in the dashboard

General payments

$6,870

324 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Priti Kothari of Boca Raton, FL is reported in the CMS Open Payments database as having received $6,870 across 324 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,542 69
2024 General $1,496 55
2023 General $1,749 76
2022 General $558 23
2021 General $103 6
2020 General $202 11
2019 General $1,221 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Priti Kothari
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Priti Kothari were reported at $1,542. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Priti Kothari Child & Adolescent Psychiatry median Middle half National median
2019 $1,221 $129 $42–$419 $163
2020 $202 $81 $28–$226 $114
2021 $103 $115 $31–$326 $132
2022 $558 $124 $40–$382 $149
2023 $1,749 $130 $45–$420 $160
2024 $1,496 $141 $42–$490 $164
2025 $1,542 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Corium, Inc. $1,612 75 payments
  2. AbbVie, Inc. $1,138 56 payments
  3. Tris Pharma Inc $741 42 payments
  4. Supernus Pharmaceuticals, Inc. $475 21 payments
  5. Neos Therapeutics, LP $299 20 payments
  6. Allergan Inc. $258 21 payments
  7. Lilly USA, LLC $250 2 payments
  8. Teva Pharmaceuticals USA, Inc. $235 2 payments
  9. Ironshore Pharmaceuticals Inc. $211 13 payments
  10. Collegium Pharmaceutical, Inc. $172 11 payments
  11. Other $1,479 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,870 324 payments
Products named General payments · program years 2019–2025
  1. Azstarys $1,612 75 payments
  2. VRAYLAR Neuroscience $924 47 payments
  3. Dyanavel XR $610 33 payments
  4. VRAYLAR Neuroscience $469 29 payments
  5. Qelbree Viloxazine Hydrochloride $338 15 payments
  6. Adzenys XR-ODT $219 15 payments
  7. COTEMPLA XR-ODT $219 15 payments
  8. Jornay PM $172 11 payments
  9. VYVANSE $166 13 payments
  10. QELBREE Psychology $137 6 payments
  11. Other $2,110 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

590

Median for Neuropsychiatry: 88

Drug cost

$13,161

Median for Neuropsychiatry: $2,689

Branded share of claims

26.9%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Escitalopram Oxalate Generic 72 $2,117
Dexmethylphenidate Hcl Er Dexmethylphenidate Hcl Brand 18 $1,953
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 19 $1,148
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 24 $1,097
Aripiprazole Generic 18 $1,081
Thiothixene Generic 21 $1,013
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 21 $630
Alprazolam Generic 62 $603
Duloxetine Hcl Generic 13 $564
Fluoxetine Hcl Generic 73 $518

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Azstarys
  • Corium, Inc. $307
$307 — —
VRAYLAR
  • AbbVie, Inc. $284
$284 — —
Dyanavel XR
  • Tris Pharma Inc $137
$137 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $125
$125 — —
Otezla
  • Amgen Inc. $125
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

324 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record